Updated:
PAREXEL International Corporation
PAREXEL International is a global CRO with 24,000+ professionals, providing Phase I-IV clinical trials, regulatory strategy, and ParexelAI.
PAREXEL International Corporation
PAREXEL International was established over 35 years ago and is headquartered in Durham, North Carolina. The firm operates as one of the world's largest clinical research organizations (CROs), providing biopharmaceutical services that span the full drug development lifecycle. Its leadership team includes senior executives focused on therapeutic areas such as cell and gene therapies, oncology, and neuroscience. The firm's core business covers Phase I through IV clinical trials, regulatory strategy, market access planning, and value substantiation. It deploys a proprietary AI-enabled clinical development suite called ParexelAI to accelerate patient outcomes. Confirmed areas of clinical focus include neuroscience, general medicine, infectious disease and vaccines, immunology, oncology, hematology, ophthalmology, cell and gene therapies, pediatrics, and rare diseases. The firm has a global footprint with operations across North America, South America, Europe, Asia-Pacific, and the Middle East and Africa. PAREXEL employs more than 24,000 professionals worldwide, making it one of the largest dedicated CROs. The firm's expertise is supported by a network of patient advocacy groups and site collaborations, including initiatives like the "Enabling Successful Sites" thought leadership series. In recent years, the firm has emphasized patient-guided drug development and launched the Clinical Trialblazers podcast to share stories behind breakthrough innovations. A structural differentiator is PAREXEL's integration of a proprietary AI suite, ParexelAI, which combines the company's operational expertise with artificial intelligence to accelerate clinical development. This positions the firm not just as a service provider but as a technology-enabled partner in biopharmaceutical innovation.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Durham
Corporate office
Durham, NC, United States
Principals
Chris Learn
Vice President, Cell and Gene Therapy, Center of Excellence
Steve Winitsky
Senior Vice President
Stefan Zietze
Executive Director
Hicham El Bariqi
Director, Cell & Gene Therapy
Jingke Yang
Senior Medical Director
Sector focus
Frequently asked questions
Who runs investment decisions at PAREXEL International?
PAREXEL is a clinical research organization rather than an investment firm. The leadership team is composed of executives such as Senior Vice President Steve Winitsky and Vice President Chris Learn, who oversee the firm's cell and gene therapy and other therapeutic areas (per the firm's website). Strategic and operational decisions are made by the executive leadership, whose full roster is listed on the firm's about page.
How does PAREXEL source proprietary deal flow?
As a contract research organization, PAREXEL does not follow a traditional investment deal flow model. The firm generates revenue by providing clinical development services to biopharmaceutical clients, including Phase I-IV trials, regulatory strategy, and market access planning. Client relationships are built through its therapeutic expertise and global operational reach.
Is PAREXEL structured as a single family office or does it operate more like a venture firm?
PAREXEL International is a publicly traded contract research organization (CRO), not a family office or venture capital firm. It operates as a service provider to the biopharmaceutical industry, managing clinical trials and drug development processes. The firm does not deploy capital as an allocator.
Does PAREXEL participate in fund commitments or only direct deals?
PAREXEL does not participate in fund commitments or direct investments. The firm's business model is based on providing clinical research services, including clinical trials, regulatory consulting, and market access support, to pharmaceutical and biotechnology companies. Its revenue comes from service contracts, not from capital allocation.
What investment stages does PAREXEL typically target?
PAREXEL specializes in clinical development services spanning Phase I through Phase IV trials. This covers early-stage investigational drug studies through post-market surveillance. The firm also offers portfolio management and asset valuation, early development and innovation, and approval and access support.
Which sectors does PAREXEL explicitly avoid?
The firm does not publicly disclose excluded sectors. Its stated therapeutic areas include neuroscience, general medicine, infectious disease and vaccines, immunology, oncology, hematology, ophthalmology, cell and gene therapies, pediatrics, and rare diseases. No explicit avoided sectors are listed.
Where does the underlying wealth come from?
PAREXEL is a publicly traded corporation, not a family office. Its revenue is generated through client contracts for clinical research services. The firm does not manage external wealth or disclose a wealth origin outside the context of its own corporate finances.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: